Horsham, P.A.; May 14, 2019 – Clinical Ink, a global clinical trial technology company that is transforming the clinical trial experience, is pleased to announce that Jonathan Andrus, Chief Business Officer at Clinical Ink, will receive the 2019 Excellence in Service Award from the Drug Information Association’s (DIA) Americas Regional Advisory Council. Andrus is being recognized for his contributions to the advancement of DIA’s mission, an honor annually bestowed on the organization’s most active members.
“After 20+ years of involvement with DIA, this moment only reignites my passion for changing the future of global health,” said Andrus. “It truly marks a renewed desire to continue to revolutionize clinical research with Clinical Ink’s future-built platforms and vision of eliminating paper source documents in clinical research.”
Like DIA’s mission to foster innovation and improve health and well-being worldwide, Clinical Ink is committed to dramatically reducing the cost and complexity of clinical research for sites, sponsors, and patients. Its pioneering EDC replacement, eCOA, and ePRO solutions are designed to support paperless clinical trials and make capturing, validating, and sharing data electronically both cleaner and faster, which ultimately helps accelerate new treatments to patients who need them.
Clinical Ink has completed over 200 studies — with experience in phase I, II, and III studies. Visit Andrus and the rest of the Clinical Ink team in Booth 2537 at DIA’s global, annual meeting to learn more about their EDC replacement, eCOA, and ePRO solutions.
Andrus will be delivering two presentations on Tuesday, June 25, at DIA’s global, annual meeting in San Diego, CA. At 2 p.m., he will join FDA and MHRA speakers to discuss: Electronic Systems: Are Yours Fit for Purpose? His 4:15 p.m. presentation is titled: Real World Evidence: How Does it Use Challenge Quality and Compliance Programs? In this presentation, he will be joined by speakers from the FDA and the MHRA.
About Clinical Ink
Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the company’s proven and future-built eSource platform, which includes solutions for EDC replacement, eCOA, ePRO, and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market.